一是A D C類藥物Sacituzumab Govitecan, , 另外一個是Atezo/Abraxane combo.可能中國也在臨床範圍之內。三陰比較凶險,複發後一般化療藥效果有限。
一是A D C類藥物Sacituzumab Govitecan, , 另外一個是Atezo/Abraxane combo.可能中國也在臨床範圍之內。三陰比較凶險,複發後一般化療藥效果有限。
WENXUECITY.COM does not represent or guarantee the truthfulness, accuracy, or reliability of any of communications posted by other users.
Copyright ©1998-2024 wenxuecity.com All rights reserved. Privacy Statement & Terms of Use & User Privacy Protection Policy